X0202 SCHEDULE 13G 0001270925 XXXXXXXX LIVE Class A Common Stock 08/19/2026 0001837607 AEON Biopharma, Inc. 00791X209 130 VANTIS DRIVE, SUITE 170 ALISO VIEJO CA 92656 Rule 13d-1(c) Timothy P. Lynch X1 6500000 0 6500000 0 6500000 13.0 IN The securities reported herein exclude prefunded warrants to purchase 1,000,000 shares of Class A Common Stock and milestone warrants to purchase 6,000,000 shares of Class A Common Stock. Those warrants may not be exercised to the extent that, after giving effect to such exercise, the reporting person would beneficially own more than 4.99% of the outstanding shares of Class A Common Stock. As a result, the reporting person cannot currently exercise any of the warrants. The percentages reported in this Schedule 13G are based on 49,882,790 shares of Class A Common Stock outstanding as of August 6, 2026, as reported in the Form 10-Q filed by the Issuer for the quarter ended June 30, 2026. AEON Biopharma, Inc. 130 VANTIS DRIVE, SUITE 170, ALISO VIEJO, CA, 92656 Timothy P. Lynch 70 SW Century Dr, STE 100 PMB 1257 Bend, OR 97702 USA Y 6,500,000 13.0% 6,500,000 0 6,500,000 0 Y Y Y Y Y N By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11. Timothy P. Lynch /s/ Timothy P. Lynch 08/21/2026